---
title: "AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301175332.md"
description: "ArriVent BioPharma (AVBP) shares plummeted over 50% after its Phase 3 FURVENT trial for firmonertinib missed its primary endpoint. SueWallSt, represented by Levi & Korsinsky LLP, has launched an investigation into potential securities law violations regarding misleading statements about the trial's prospects. Investors who suffered losses are encouraged to submit their information for a review of potential recovery claims."
datetime: "2026-10-07T18:20:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301175332.md)
  - [en](https://longbridge.com/en/news/301175332.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301175332.md)
generator: "portal-rs"
---

# AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma

This news item displays a headline only and has no other text.

### Related Stocks

- [AVBP.US](https://longbridge.com/en/quote/AVBP.US.md)

## Related News & Research

- [ArriVent doses first patient in Phase 1 trial of ARR-002 dual-target ADC for ovarian, endometrial cancer](https://longbridge.com/en/news/301620875.md)
- [ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)](https://longbridge.com/en/news/301079950.md)
- [ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low](https://longbridge.com/en/news/301066580.md)
- [ArriVent says Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC misses primary PFS endpoint](https://longbridge.com/en/news/301032671.md)
- [IonQ Pays $1.3B in Stock for Cybersecurity — What Shareholders Are Giving Up](https://longbridge.com/en/news/301615441.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**